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Purpose: Tumors arising from the ampulla of Vater can be benign or malignant. Recently, endoscopic papillectomy has been 
employed in the management of benign ampulla of Vater tumors; however, surgical resection is the treatment of choice. The 
aim of this study was to define indications and suggest a role for transduodenal ampullectomy in the management of ampul-
la of Vater tumors. Methods: We retrospectively reviewed the medical records of 54 patients treated for ampulla of Vater tu-
mors between January 1999 and December 2008. Results: Twenty-two endoscopic papillectomies and 21 transduodenal am-
pullectomies were performed. Four patients underwent transduodenal ampullectomy after endoscopic papillectomy due to 
a recurrent or remnant tumor. Recurrence or a remnant tumor was found in one patient after transduodenal ampullectomy 
compared to six patients after endoscopic papillectomy. Immediate intraoperative conversion from transduodenal ampullec-
tomy to pancreaticoduodenectomy was performed in five patients based on intraoperative frozen biopsy analysis. 
Conclusion: Transduodenal ampullectomy should be performed to treat ampulla of Vater tumors that are unsuitable for en-
doscopic papillectomy. Transduodenal ampullectomy can serve as an intermediate treatment option between endoscopic 
papillectomy and pancreaticoduodenectomy in the management of ampulla of Vater tumors. 
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INTRODUCTION
Tumors of the ampulla of Vater have various histo-
pathologic characteristics that can be benign or malignant. 
It is difficult to achieve an accurate diagnosis and exclude 
malignancy based on preoperative studies because of the 
possibility of an invasive carcinoma within an adenoma. 
Endoscopic papillectomy has recently been used to man-
age periampullary adenomas [1-4], but curative surgical 
resection remains the treatment of choice [5-7].
Transduodenal ampullectomy was first introduced by 
Halstead in 1899 [8], and was initially attempted as treat-
ment for ampulla of Vater cancer. The use of this proce-
dure failed to become widespread because the surgical 
technique had not been standardized and the recurrence 
rate was high. Since Whipple introduced pancreatico-
duodenectomy in 1935 [9], it has been recommended as 
the definitive surgery for ampulla of Vater lesions [6,7,10]. 
The performance of transduodenal ampullectomy has 
been reported in limited cases and in a small number of Role of transduodenal ampullectomy
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series. No specific consensus has been reached regarding 
the indications for transduodenal ampullectomy, and 
there are few studies that address the role of trans-
duodenal ampullectomy with respect to its relationship 
with endoscopic papillectomy [11-14]. The aim of this 
study was to define indications and suggest a role for 
transduodenal ampullectomy in the management of am-
pulla of Vater tumors based on a review of experience at a 
single center .
METHODS
The medical records of 54 patients with ampulla of 
Vater tumors treated at the Samsung Medical Center be-
tween January 1999 and December 2008 were retro-
spectively reviewed. All patients underwent an esoph-
agoduodenoscopic (EGD) exam and biopsy. Computed 
tomography (CT) or endoscopic ultrasonography (EUS) 
was performed to assess the extent of the tumor. Patients 
with a malignancy confirmed by preoperative biopsy 
were excluded from this study.
Patients were initially treated by endoscopic papillec-
tomy, transduodenal ampullectomy, or pancreaticoduo-
denectomy, depending on tumor size, the presence of 
high-grade dysplasia on endoscopic biopsy, and suspi-
cions of malignancy on preoperative imaging studies. 
Endoscopic papillectomy was performed initially in pa-
tients with a benign-looking tumor or a tumor size less 
than 2 cm. Prior to endoscopic papillectomy, a pancreato-
gram and a cholangiogram were obtained by endoscopic 
retrograde cholangiopancreatography (ERCP) in order to 
check for ductal involvement. En bloc resection was at-
tempted in all patients, and when this failed, piecemeal re-
section was performed. After papillectomy, a pancreatic 
stent and a biliary stent were inserted to prevent post pap-
illectomy pancreatitis and stenosis. Chest radiography 
and laboratory tests were performed for all patients to 
screen for microperforations, pancreatitis, and bleeding 
after papillectomy. EGD was performed for stent removal 
2 to 5 days after initial endoscopic papillectomy. Follow- 
up EGD was performed at three to six months intervals for 
two years, and annual EGD examination was recom-
mended thereafter. If any suspicious mucosal nodularity 
was found on EGD during follow-up, biopsy was per-
formed and histologic results were reviewed. A remnant 
lesion was defined as a biopsy-confirmed lesion within a 
suspicious adenomatous lesion at a previous papil-
lectomy site on subsequent EGD. Recurrence was defined 
as a lesion detected six months after treatment with at least 
one EGD biopsy result showing no residual lesion [15].
When patients were not suitable for endoscopic papil-
lectomy (a tumor greater than 2 cm, a tumor with intra-
ductal growth, or a lateral spreading tumor) transduo-
denal ampullectomy was performed as the initial treat-
ment. Transduodenal ampullectomy was attempted as the 
initial treatment in patients with any suspicious sign of 
malignancy on preoperative study, such as high-grade 
dysplasia on preoperative endoscopic biopsy.
Transduodenal ampullectomy was performed as de-
scribed in other studies [12,14,16-18]. The operative proce-
dure included the Kocher maneuver, longitudinal duode-
notomy, full thickness excision of the ampulla, and re-im-
plantation of the common bile duct and the pancreatic 
duct into the duodenal wall. Cholecystectomy was per-
formed routinely. Short stents were inserted into the pan-
creatic ducts to prevent pancreatitis. Tumors, the bile duct 
and the pancreatic duct margin were sent to pathology for 
intraoperative frozen section review. Routine lymph node 
dissection was not performed.
Ten patients who underwent pancreaticoduodenec-
tomy as an initial treatment because of a suspected malig-
nancy on preoperative study, but for whom final pathol-
ogy revealed a benign tumor, were also included in this 
study. Patient demographics, symptoms, and preopera-
tive endoscopic biopsy and final pathology findings were 
reviewed. Post-operative outcomes were evaluated with 
respect to length of hospital stay, and post-operative com-
plications and recurrence during follow-up. 
RESULTS
A total of 54 patients with an ampulla of Vater tumor 
were included in this retrospective review; 25 were female 
and 29 were male. Thirty-seven patients were asympto-Jieun Kim, et al.
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Table 1. Presenting symptoms and signs
Symptoms & signs No. of patients
Screening  test 36
Jaundice   8
Abdominal pain   7
Dyspepsia   2
General weakness   1
Total 54
Fig. 1. Diagram of patients flow. 




tumor, margin (+). 
b)Remnant tumor. 
c)Remnant tumor, Lat. spreading 
type. 
d)Recurrence, P-duct stricture. 
e)Frozen: 3 adenocarcinoma, 1 car-
cinoid very close margin. 
f)Frozen; 
deep mucosal bile duct margin (+). 
g)Final pathology: benign.
Table 2. Comparison between results of endoscopic papillectomy 
vs. transduodenal ampullectomy (TDA)
Endoscopic 
papillectomy (n = 22)
TDA (n = 21)
Hospital stay (day)   5 (3-12)  9 (7-37)
Follow up (months) 10 (1-64) 18 (1- 72)
Complications 11 5
Recur/remnant  6 1
Resection margin (＋) 3 1
matic and found to have an abnormality on screening tests 
such as EGD. The median patient age was 58 years (range, 
37 to 75 years). Eighteen patients presented with symp-
toms including jaundice (8 patients), abdominal pain (7 
patients), dyspepsia (2 patients) or general weakness (1 
patient) (Table 1). Endoscopic papillectomy was selected 
as the initial treatment in 22 patients while 32 patients 
were initially treated with surgery (22 with transduodenal 
ampullectomy and 10 with pancreaticoduodenectomy) 
(Fig. 1).
Ten patients had no recurrence after endoscopic papil-
lectomy, and nine patients underwent additional endo-
scopic papillectomy or ERCP biopsy after endoscopic pap-
illectomy for a remnant adenoma or a positive resection 
margin (Fig. 1). Two patients had remnant adenoma after 
the second endoscopic papillectomy and subsequently 
underwent transduodenal ampullectomy (Fig. 1). Imme-
diate conversion to pancreaticoduodenectomy was per-
formed in one of these two patients because of a positive 
deep mucosal bile duct margin on intraoperative frozen 
section analysis (Fig. 1). One patient was found to have a 
remnant lateral spreading tumor after endoscopic papil-
lectomy. Surgery was recommended, but the patient was 
unfortunately lost to follow-up (Fig. 1). Two patients even-
tually underwent transduodenal ampullectomy for a rem-
nant tumor and a pancreatic duct stricture after papil-
lectomy (Fig. 1).
Of the 22 patients for whom transduodenal ampullec-
tomy was initially attempted, 4 patients were converted to 
pancreaticoduodenectomy after intraoperative frozen bi-
opsy analysis. Of these four patients, three had ad-
enocarcinoma and the other had a carcinoid with a very 
close margin (Fig. 1).
As a result, 22 patients underwent endoscopic papil-
lectomy while 21 patients underwent transduodenal 
ampullectomy. Five patients had immediate intraopera-
tive conversion from transduodenal ampullectomy to 
pancreaticoduodenectomy (Fig. 1). The median hospital 
stay after endoscopic papillectomy was 5 days (range, 3 to Role of transduodenal ampullectomy
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Table 3. Complications of endoscopic papillectomy and 
transduodenal ampullectomy (TDA)
Endoscopic 
papillectomy (n = 22)
TDA (n = 21)
Pancreatitis 6 Delayed gastric emptying 1
Bleeding 3 Wound dehiescence 1
Microperforation 1 Passage disturbance1 1
P-duct stricture 1 Pancreatitis
   P-duct stenosis 2
  Papilla orifice stenosis
Total 11 5
Table 5. Pathology of transduodenal ampullectomy
Pre op Frozen biopsy Final No. of cases
Chronic duodenitis  (－) Chronic inflammation 1
Spindle cell tumor Gangliocystic paraganglioma 1
Adenomyoma Epithelial hyperplasia Adenomyoma 1
Adenoma, LGD Pancreatic tissue Pancreatic heterotopia 1
Adenoma Adenoma 5
AoV IPMN, Minimally invasive ca 1
Focal HGD TA c focal HGD 2
CIS
Malignancy Adenoca, Adenomyoma 1
Adenoma, HGD Adenomatous lesion Adenomyoma 1
(－)T A  c  H G D 1
Adenoma LGD Adenoma LGD 1
TVA c focal HGD 1
No malignancy TA c HGD,  Adenoca 1
Focal atypical gland TA c focal HGD 1
Mucosal lesion, adenoma TVA c HGD, CIS 1
Atypical gland Adenoca. Margin (－) Adenoca. lateral focal deep margin (+) 1
Total 21
LGD, low grade dysplasia; HGD, high grade dysplasia; CIS, carcinoma in situ; IPMN, intraductal papillary mucinous neoplasm; TA, tubular 
adenoma; TVA, tubulovillous adenoma.
Table 4. Pathology of endoscopic papillectomy
Pathology No. of cases
Adenoma, LGD
　Tubular   9
　Tubulo villous   5
　Villous   1
Adenoma, HGD
　Tubular   3
　Tubulo villous   1
Ampullary adenomyoma   2
Ganglioneuroma   1
Total 22
LGD, low grade dysplasia; HGD, high grade dysplasia.
12 days), which was shorter than the 9 days (range, 7 to 37 
days) required after transduodenal ampullectomy (Table 
2). The median follow-up period for endoscopic papil-
lectomy was 10 months (range, 1 to 64 months), and that of 
transduodenal ampullectomy was 18 months (range, 1 to 
72 months).
Complications
Complications were observed in 11 and 5 patients after 
endoscopic papillectomy and transduodenal ampullec-
tomy, respectively (Table 3); no deaths occurred after ei-
ther procedure. The complications that occurred after en-
doscopic papillectomy were pancreatitis, bleeding, and 
microperforation. Ten patients with complications had a 
longer hospital stay than average, but all improved with 
conservative treatment only. One female patient under-
went transduodenal ampullectomy eight months after the 
initial procedure because of a pancreatic duct stricture. 
The complications that occurred after transduodenal am-
pullectomy were delayed gastric emptying, wound de-
hiscence, passage disturbance, p-duct stenosis-induced 
pancreatitis, and biliary stricture-induced cholangitis. 
With the exception of one patient with delayed gastric 
emptying, the others underwent intervention or surgery Jieun Kim, et al.
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Fig. 2. (A) Microphotograph of specimen of transduodenalampullectomy. Focal minimally invasive carcinoma (＜5%) in the background of 
high grade dysplasia (circle) (H&E, ×10). (B) Magnification view of focal invasive mucinous carcinoma, marked with circle in Fig. 2A  (H&E, 
×100). 
for treatment of their complications. 
Pathology
Of the 22 cases that underwent endoscopic papil-
lectomy, 15 had a final pathologic diagnosis of low grade 
adenoma (Table 4). Pathology results after transduodenal 
ampullectomy ranged from low grade adenoma to ad-
enocarcinoma (Table 5). The accuracy of preoperative en-
doscopic biopsy versus final pathology was 47.6% (10 of 21 
patients), and the accuracy of intraoperative frozen biopsy 
analysis versus final pathology was 65.2% (15 of 23 pa-
tients); frozen section biopsy analysis was not performed 
in two patients.
Ampulla of Vater cancer was suspected in one patient 
with liver cirrhosis due to chronic hepatitis B infection. 
However, transduodenal ampullectomy was performed 
instead of pancreaticoduodenectomy because of the risk 
of postoperative hepatic failure. The ultimate biopsy re-
sult in this case was adenocarcinoma with a positive later-
al focal deep margin. The patient subsequently underwent 
adjuvant radiotherapy and there was no evidence of re-
currence after 24 months of follow-up. 
Five of 22 patients had focal carcinoma or carcinoma in 
situ according to the final pathology report; all carcinomas 
were confined to mucosa. One patient with a final patho-
logic diagnosis of adenocarcinoma within adenomyoma 
with a negative resection margin experienced recurrence 
at 33 months postoperatively. A metastatic seeding nodule 
was found, and this patient was treated with concurrent 
chemo-radiation therapy.
DISCUSSION
Screening esophagogastroduodenoscopy has been per-
formed actively over the last decade, and has increased the 
detection rate of asymptomatic ampulla of Vater tumors 
[1,2,5,15]. Clinicians are concerned about the proper man-
agement of this type of tumor, and radical resection with 
pancreaticoduodenectomy is widely accepted as the de-
finitive treatment; however the perioperative morbidity 
and mortality associated with this procedure are problem-
atic [19,20].
Endoscopic papillectomy is an attractive method for 
treating ampulla of Vater tumors because it reduces the 
possibility of laparotomy. However, endoscopic papil-
lectomy is inconvenient to patients because frequent en-
doscopic examinations are required after the procedure 
[5,21,22]. Furthermore, specimens obtained after piece-
meal resection may have inadequate margins or false neg-Role of transduodenal ampullectomy
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Fig. 3. Flowsheet of recommen-
dation for management of AoV 
tumors. HGD, high grade dysplasia; 
LGD, low gradedysplasia; CT, com-
puted tomography; EUS, endosco-




ative results, therefore close monitoring for recurrent or 
remnant tumors is recommended. In the present study, 
three positive resection margins and six remnant tumors 
were found after 22 endoscopic papillectomies, as com-
pared with one recurrence and one positive resection mar-
gin after 21 transduodenal ampullectomies.
The advantage of transduodenal ampullectomy is that 
it allows complete circumferential resection of the ampul-
la of Vater, which enables precise pathologic examination. 
Fig. 2 is a photomicrograph of a specimen obtained after 
transduodenal ampullectomy with predominantly high- 
grade dysplasia in the background and a less than 5% focal 
minimally invasive carcinoma. Had endoscopic papil-
lectomy been performed on this patient, the focal carcino-
ma would likely have been missed. Accordingly, if it is not 
possible to obtain a clear resection margin by en bloc re-
section in endoscopic papillectomy, the patient should un-
dergo transduodenal ampullectomy rather than piece-
meal resection. An inadequate resection margin could not 
only result in tumor recurrence, but may also preclude the 
chance to diagnosis focal or in situ carcinoma within an 
adenoma.
The standard procedure for transduodenal ampullec-
tomy includes re-implantation of the bile duct and p-duct, 
and post-operative pancreatitis is therefore rarely encoun-
tered [12,14,16,17,23]. Furthermore, intraoperative frozen 
section examinations provide another opportunity for im-
mediate conversion to pancreaticoduodenectomy if in-
vasive carcinoma is found. Ten patients underwent pan-
creaticoduodenectomy initially (Fig. 1) due to suspected 
malignancy on preoperative study, but final pathologic di-
agnosis was benign. If transduodenal ampullectomy had 
been attempted on these patients, pancreaticoduodenec-
tomy could have been avoided.
The limitations of this study are 1) Endoscopic papil-
lectomy has been actively performed at our institute over 
recent years; 2) Outcomes may have varied depending on 
the techniques employed by individual endoscopists; and 
3) The mean follow-up duration for patients who under-
went endoscopic papillectomy or transduodenal ampul-
lectomy was less than 24 months. Further studies with a 
longer follow-up are required.
In conclusion,  transduodenal ampullectomy should be 
indicated for patients in whom an adequate resection mar-
gin was not obtained with endoscopic papillectomy and in 
patients with high grade dysplasia on endoscopic biopsy. 
We recommend that transduodenal ampullectomy should 
be strongly considered for recurrent or remnant tumors af-
ter endoscopic papillectomy in order to obtain an ad-
equate resection margin and to provide definite treatment 
[11-14,24,25]. Because frozen biopsy allows immediate in-
traoperative conversion to pancreaticoduodenectomy, 
transduodenal ampullectomy could act as an intermediate 
step between endoscopic papillectomy and pancreatico-
duodenectomy for the treatment of ampulla of Vater tu-
mors (Fig. 3) [26,27]. Use of this technique initially could 
prevent unnecessary pancreaticoduodenectomy in benign 
ampulla of Vater tumors [28].Jieun Kim, et al.
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